New drug trial aims to slow devastating ALS progression
NCT ID NCT07174492
Summary
This study is testing whether adding an oral drug called masitinib to the standard ALS medication (riluzole) can slow the progression of the disease better than riluzole alone. It will involve 412 adults with ALS and will measure changes in their physical abilities and quality of life over 48 weeks. The goal is to see if masitinib can reduce inflammation in the nervous system to help patients maintain function for longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aiginition Hospital
Athens, Greece
Contact
Conditions
Explore the condition pages connected to this study.